HIV-1 dynamics and coreceptor usage in maraviroc-treated patients with ongoing replication

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 930-935

  Recordon Pinson, P ^a   Raymond, S ^a   Marcelin, P ^b   Marcelin, A G ^c   Soulie, C ^d   Descamps, D ^d   Calvez, V ^a,b   Harrigan, P R ^e,f   Fleury, H ^a,c,f   Izopet, J ^a   Masquelier, B ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

^e BICHAT HOSPITAL   (France)

^f BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; DARUNAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENETIC SELECTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MOLECULAR EVOLUTION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SPECIES; VIRAL TROPISM; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

CYCLOHEXANES; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SELECTION, GENETIC; SEQUENCE ANALYSIS, RNA; TRIAZOLES; VIRAL TROPISM;

EID: 84872834215     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02159-12     Document Type: Article

References (21)

1. Cicala C, Arthos J, Fauci AS. 2011. HIV-1 envelope, integrins and coreceptor use in mucosal transmission of HIV. J. Transl. Med. 9:S2.
2. MacArthur RD, Novak RM. 2008. Reviews of anti-infective agents: Maraviroc: The first of a new class of antiretroviral agents. Clin. Infect. Dis. 47:236-241.
3. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T. 2006. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 352:477-484.
4. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
5. Berro R, Klasse PJ, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP. 2011. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol. 85:8227-8240.
6. Moore JP, Kuritzkes DR. 2009. A pièce de resistance: How HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4:118-124.
7. Wirden M, Soulié C, Fourati S, Valantin MA, Simon A, Ktorza N, Tubiana R, Bonmarchand M, Schneider L, Calvez V, Katlama C, Marcelin AG. 6 September 2012. Pitfalls of HIV genotypic tropism testing after treatment interruption. J. Antimicrob. Chemother. [Epub ahead of print.] doi:10.1093/jac/dks362.
8. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antag-onist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
9. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
10. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD. 2009. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS Clinical Trials Group A5211. J. Infect. Dis. 200:1724-1728.
11. Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group. 2010. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: The ANRS GenoTropism Study. Antimicrob. Agents. Chemother. 54:3335-3340.
12. Letunic I, Bork P. 2007. Interactive Tree Of Life (iTOL): An online tool for phylogenetic tree display and annotation. Bioinformatics 23:127-128.
13. Saliou A, Delobel P, Dubois M, Nicot F, Raymond S, Calvez V, Masquelier B, Izopet J; ANRS AC11 Resistance Study Group. 2011. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob. Agents. Chemother. 55: 2831-2836.
14. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep sequencing to infer HIV-1 co-receptor usage: Application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203:237-245.
15. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Bruel P, Sandres-Sauné K, Marchou B, Massip P, Izopet J. 2010. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J. Clin. Virol. 47:126-130.
16. Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, Parkin N, Petropoulos CJ. 2008. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol. 82:5584-5593.
17. Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, Reitz M. 2008. An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J. Virol. 82:5460-5471.
18. Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. 2010. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84:10863-10876.
19. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
20. Lewis M, Mori J, Simpson P. 2008. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials, abstr 871. Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA.
21. Lewis M, Simpson P, Delogne C. 2010. Genotypic analysis of the HIV-1 gp120 V3 loop for treatment-experienced patients enrolled into the MOTIVATE studies and who received maraviroc-optimized background therapy, abstr 539. Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.